WHO ICTRP trial
Single-Arm, prospective clinical trial of Camrelizumab combined with apatinib…
ChiCTR2100051989 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2100051989 |
|---|---|
| Public title | Single-Arm, prospective clinical trial of Camrelizumab combined with apatinib mesylate for preoperative induction and postoperative maintenance in patients with oral cancer |
| Scientific title | Single-Arm, prospective clinical trial of Camrelizumab combined with apatinib mesylate for preoperative induction and postoperative maintenance in patients with oral cancer |
| Primary sponsor | The First Affiliated Hospital of Zhengzhou University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Oral cancer |
| Interventions | Experimental group:Camrelizumab combined with apatinib mesylate |
| Registration date | Oct 12, 2021 |
| Target size | Experimental group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: